NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. META
10. TLT

Go back to NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
(NASDAQ: ELDN) Delayed: 2.65 -0.02 (0.75%)
Previous Close $2.67    52 Week High $ 
Open $2.73    52 Week Low $ 
Day High $2.79    P/E N/A 
Day Low $2.62    EPS $ 
Volume 556,015